Interleukin-6 in renal disease and therapy

Simon Arnett Jones; Donald James Fraser; Ceri Alan Fielding; Gareth Wyn Jones

doi:10.1093/ndt/gfu233

Interleukin-6 in renal disease and therapy

Simon Arnett Jones, Donald James Fraser, Ceri Alan Fielding, Gareth Wyn Jones

Research output: Contribution to journal › Article (Academic Journal) › peer-review

67 Citations (Scopus)

Abstract

Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease.

Original language	English
Pages (from-to)	564-574
Number of pages	11
Journal	Nephrology Dialysis Transplantation
Volume	30
Issue number	4
Early online date	10 Jul 2014
DOIs	https://doi.org/10.1093/ndt/gfu233
Publication status	Published - Apr 2015

Access to Document

10.1093/ndt/gfu233

Handle.net

Persistent link

Cite this

@article{fadbc8c9159b496cbca9150a8bfd3e6c,

title = "Interleukin-6 in renal disease and therapy",

abstract = "Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease.",

author = "Jones, {Simon Arnett} and Fraser, {Donald James} and Fielding, {Ceri Alan} and Jones, {Gareth Wyn}",

year = "2015",

month = apr,

doi = "10.1093/ndt/gfu233",

language = "English",

volume = "30",

pages = "564--574",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Interleukin-6 in renal disease and therapy

AU - Jones, Simon Arnett

AU - Fraser, Donald James

AU - Fielding, Ceri Alan

AU - Jones, Gareth Wyn

PY - 2015/4

Y1 - 2015/4

N2 - Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease.

AB - Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease.

UR - http://orca.cf.ac.uk/78708/

U2 - 10.1093/ndt/gfu233

DO - 10.1093/ndt/gfu233

M3 - Article (Academic Journal)

C2 - 25011387

SN - 0931-0509

VL - 30

SP - 564

EP - 574

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 4

ER -

Interleukin-6 in renal disease and therapy

Abstract

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this